Circulating level of Th17 cells is associated with sensitivity to glucocorticoids in patients with immune thrombocytopenia.
Glucocorticoids are a widely recognized first-line therapy for immune thrombocytopenia (ITP). However, some patients are unresponsive to glucocorticoid therapy for reasons that remain unclear. Accumulating evidence suggests that CD4+ T-cell abnormalities play a crucial role in the development of ITP. In the present study, we investigated peripheral blood CD4+ T cells, Th17-associated cytokines, and the mRNA expression level of Th17 transcription factor-RORγt-in patients with newly-diagnosed ITP before glucocorticoid therapy. The study involved 27 newly-diagnosed patients. Th17-cell levels in the peripheral blood of newly-diagnosed ITP patients were associated with responsiveness to glucocorticoid therapy. Newly-diagnosed ITP patients who were not sensitive to glucocorticoid treatment were found to have lower levels of Th17 cells. Quantifying Th17 cells may allow physicians to predict prognosis of glucocorticoid treatment and stratify therapy for those with ITP. This strategy may provide a new approach to the treatment of glucocorticoid-insensitive patients.
['Zhang|YiChan|Y|', 'Ma|TingTing|T|', 'Zhou|Xuan|X|http://orcid.org/0000-0003-4503-0732', 'Chen|JunHao|J|', 'Li|Juan|J|']
D000293:Adolescent D000328:Adult D000368:Aged D000369:Aged, 80 and over D015496:CD4-Positive T-Lymphocytes D002478:Cells, Cultured D016207:Cytokines D004351:Drug Resistance D005260:Female D005544:Forecasting D015870:Gene Expression D005938:Glucocorticoids D006801:Humans D008297:Male D008875:Middle Aged D057132:Nuclear Receptor Subfamily 1, Group F, Member 3 D011379:Prognosis D016553:Purpura, Thrombocytopenic, Idiopathic D012333:RNA, Messenger D058504:Th17 Cells D055815:Young Adult
Th17 cells Immune thrombocytopenia (ITP) Glucocorticoid sensitivity